Interactions among myeloid regulatory cells in cancer
Samo za registrovane korisnike
2019
Autori
Umansky, Viktor
Adema, Gosse J.
Baran, Jaroslaw

Brandau, Sven
Van Ginderachter, Jo A.

Hu, Xiaoying
Jablonska, Jadwiga

Mojsilović, Slavko

Papadaki, Helen A.
de Coana, Yago Pico

Santegoets, Kim
Santibanez, Juan

Serre, Karine
Si, Yu
Sieminska, Isabela
Velegraki, Maria
Fridlender, Zvi G.
Članak u časopisu (Objavljena verzija)

Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppressi...on. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells.
Ključne reči:
Myeloid regulatory cells / Mye-EUNITER / Macrophages / Neutrophils / Myeloid-derived suppressor cells / Dendritic cellsIzvor:
Cancer Immunology Immunotherapy, 2019, 68, 4, 645-660Izdavač:
- Springer, New York
Finansiranje / projekti:
- COST action
- COST action [BM1404 - Mye-EUNITER]
- German Cancer Research Center (DKFZ) Helmholtz Association [CA181]
- Ministry of Science, Technology and Space of Israel (MOST) in Cancer Research [CA181]
DOI: 10.1007/s00262-018-2200-6
ISSN: 0340-7004
PubMed: 30003321
WoS: 000463762200012
Scopus: 2-s2.0-85049801577
Institucija/grupa
Institut za medicinska istraživanjaTY - JOUR AU - Umansky, Viktor AU - Adema, Gosse J. AU - Baran, Jaroslaw AU - Brandau, Sven AU - Van Ginderachter, Jo A. AU - Hu, Xiaoying AU - Jablonska, Jadwiga AU - Mojsilović, Slavko AU - Papadaki, Helen A. AU - de Coana, Yago Pico AU - Santegoets, Kim AU - Santibanez, Juan AU - Serre, Karine AU - Si, Yu AU - Sieminska, Isabela AU - Velegraki, Maria AU - Fridlender, Zvi G. PY - 2019 UR - http://rimi.imi.bg.ac.rs/handle/123456789/964 AB - Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppression. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells. PB - Springer, New York T2 - Cancer Immunology Immunotherapy T1 - Interactions among myeloid regulatory cells in cancer EP - 660 IS - 4 SP - 645 VL - 68 DO - 10.1007/s00262-018-2200-6 ER -
@article{ author = "Umansky, Viktor and Adema, Gosse J. and Baran, Jaroslaw and Brandau, Sven and Van Ginderachter, Jo A. and Hu, Xiaoying and Jablonska, Jadwiga and Mojsilović, Slavko and Papadaki, Helen A. and de Coana, Yago Pico and Santegoets, Kim and Santibanez, Juan and Serre, Karine and Si, Yu and Sieminska, Isabela and Velegraki, Maria and Fridlender, Zvi G.", year = "2019", abstract = "Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppression. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells.", publisher = "Springer, New York", journal = "Cancer Immunology Immunotherapy", title = "Interactions among myeloid regulatory cells in cancer", pages = "660-645", number = "4", volume = "68", doi = "10.1007/s00262-018-2200-6" }
Umansky, V., Adema, G. J., Baran, J., Brandau, S., Van Ginderachter, J. A., Hu, X., Jablonska, J., Mojsilović, S., Papadaki, H. A., de Coana, Y. P., Santegoets, K., Santibanez, J., Serre, K., Si, Y., Sieminska, I., Velegraki, M.,& Fridlender, Z. G.. (2019). Interactions among myeloid regulatory cells in cancer. in Cancer Immunology Immunotherapy Springer, New York., 68(4), 645-660. https://doi.org/10.1007/s00262-018-2200-6
Umansky V, Adema GJ, Baran J, Brandau S, Van Ginderachter JA, Hu X, Jablonska J, Mojsilović S, Papadaki HA, de Coana YP, Santegoets K, Santibanez J, Serre K, Si Y, Sieminska I, Velegraki M, Fridlender ZG. Interactions among myeloid regulatory cells in cancer. in Cancer Immunology Immunotherapy. 2019;68(4):645-660. doi:10.1007/s00262-018-2200-6 .
Umansky, Viktor, Adema, Gosse J., Baran, Jaroslaw, Brandau, Sven, Van Ginderachter, Jo A., Hu, Xiaoying, Jablonska, Jadwiga, Mojsilović, Slavko, Papadaki, Helen A., de Coana, Yago Pico, Santegoets, Kim, Santibanez, Juan, Serre, Karine, Si, Yu, Sieminska, Isabela, Velegraki, Maria, Fridlender, Zvi G., "Interactions among myeloid regulatory cells in cancer" in Cancer Immunology Immunotherapy, 68, no. 4 (2019):645-660, https://doi.org/10.1007/s00262-018-2200-6 . .